High-level amplification of the protein phosphatase PPM1D (WIP1) is present in a subset of medulloblastomas (MBs) that have an expression profile consistent with active Sonic Hedgehog (SHH) signaling. We found that WIP1 overexpression increased expression of Shh target genes and cell proliferation in response to Shh stimulation in NIH3T3 and cerebellar granule neuron precursor cells in a p53-independent manner. Thus, we developed a mouse in which WIP1 is expressed in the developing brain under control of the Neurod2 promoter (ND2:WIP1). The external granule layer (EGL) in early postnatal ND2:WIP1 mice exhibited increased proliferation and expression of Shh downstream targets. MB incidence increased and survival decreased when ND2:WIP1 mice were crossed with an Shh-activated MB mouse model. Conversely, Wip1 knockout significantly suppressed MB formation in two independent mouse models of Shh-activated MB. Furthermore, Wip1 knockdown or treatment with a WIP1 inhibitor suppressed the effects of Shh stimulation and potentiated the growth inhibitory effects of SHH pathway-inhibiting drugs in Shh-activated MB cells in vitro. This suggests an important cross-talk between SHH and WIP1 pathways that accelerates tumorigenesis and supports WIP1 inhibition as a potential treatment strategy for MB.
INTRODUCTION
Medulloblastoma (MB) is the most common malignant brain tumor of childhood. Unfortunately, current therapeutic regimens are associated with numerous long-term side effects. 1 And, despite clinical advances, up to 30% of children with MB experience tumor progression or recurrence, for which no cure exists. 2 Continued advances in therapy demand a better understanding of the molecular drivers of MB and treatment responsiveness.
Recent studies suggest that MB can be divided into at least four subgroups based on gene expression and methylation profile: Wingless (WNT), Sonic Hedgehog (SHH), Group 3 and Group 4.
3 One-quarter of MBs bear a signature of active SHH signaling. Clinically viable small-molecule inhibitors of SHH signaling have been developed, and phase I/II clinical trials have demonstrated efficacy of SHH-inhibiting drugs against SHH MBs. 4 Unfortunately, resistance to SHH inhibitors develops quickly, and mechanisms of resistance are not fully understood.
Cytogenetics have previously shown that one-third of MBs exhibit gain of the long arm of chromosome 17 (17q) or isochromosome 17q (i17q), which is associated with poor disease-related survival.
5 Surprisingly, the tumor suppressor gene, TP53, on chromosome 17p13, is usually wild type in most MBs that exhibit loss of heterozygosity of 17p. 6 Mutations of TP53 are constrained almost exclusively to WNT and SHH MBs and confer a dismal prognosis for survival in patients with SHH MBs. However, TP53 mutations are present in less than 10% of MBs. 7 Yet, p53
function is compromised in a larger percentage of tumors, especially in aggressive histologic subtypes of MB. 8 Northcott et al. 9 have shown that a subset of MBs that have a signature of SHH pathway activation have high-level amplification of the chromosomal locus of WIP1 (wild-type p53-induced phosphatase 1; protein phosphatase, magnesium-dependent 1, delta, PPM1D) on chromosome 17q22-q23.
We found that WIP1 overexpression in NIH/3T3 and cerebellar granule neuron precursor (cGNP) cells, a well-characterized MB cell of origin, [10] [11] [12] [13] increased expression of Shh target genes and cell proliferation in response to Shh stimulation in a p53-independent manner. WIP1 transgenic mice showed evidence of increased proliferation and expression of Shh downstream target genes in the EGL, where cGNPs arise and proliferate during early postnatal cerebellar development. When WIP1 transgenic mice were crossed with Shh-activated, SmoA1/ SmoA1 MB-prone mice, MB incidence increased and MBassociated survival decreased. Conversely, Wip1 knockout significantly suppressed MB formation in SmoA1/SmoA1 and tamoxifen-induced Math1-cre ER ; Ptc1 fl/fl mice. shRNA-mediated knockdown of Wip1 or treatment with a WIP1 inhibitor blocked the effects of Shh stimulation and potentiated the growth inhibitory effects of the SHH pathway-inhibiting drugs in SmoA1/ SmoA1 or Math1-cre ER +; Ptc1 fl/fl MB cells under cell culture conditions. This suggests an important cross-talk between SHH and WIP1 signaling that accelerates MB tumorigenesis and that may be targetable with small molecules that inhibit WIP1 function. RESULTS WIP1 promotes cell growth through SHH signaling pathways Previous studies support cross-talk between WIP1 and the SHH signaling pathway in multiple types of cancer, including MB. 14, 15 To better understand this, we used NIH/3T3 cells stably transfected with a GLI-responsive Firefly luciferase reporter and a constitutive Renilla luciferase expression vector (shh-LIGHT2) or with a Gli-dependent enhanced green fluorescent protein (EGFP) reporter (shh-EGFP), which provide downstream read-outs for activation of SHH signaling. 16, 17 Immunofluorescence (IF) detected increased GFP in yellow fluorescent protein (YFP)-WIP1 (YFP-WIP1; LentiORF-YFP-WIP1)-transduced shh-EGFP cells, following stimulation with recombinant Shh (Shh) (Figure 1a) . We also found increased expression of Firefly luciferase in Shh-stimulated, YFP-WIP1-transduced shh-LIGHT2 cells, relative to controls (Figure 1b) . Quantitative real-time, reverse transcriptase-PCR (qRT-RT-PCR) confirmed increased expression of the downstream target of Shh signaling, Gli1, following Shh stimulation (Figure 1c) . Flow cytometry revealed a significant increase in the percentage of YFP-WIP1-transduced shh-EGFP cells in the S-phase following Shh stimulation (Figure 1d ). Overall, this shows that WIP1 increases proliferation through Shh-dependent and -independent mechanisms.
WIP1 promotes hedgehog signaling through p53-independent pathways Although earlier studies have shown that WIP1 promotes growth primarily through p53 signaling pathways, recent publications suggest that the interaction between WIP1 and SHH signaling occurs independent of p53. 15 To validate this prior finding, we transduced shh-EGFP cells with either Trp53 shRNA or YFP-WIP1. In contrast to the prior report in which TP53 knockdown enhanced Shh signaling, in shh-EGFP cells, knockdown of Trp53 did not affect Shh-stimulated expression of Gli1 in the presence or absence of WIP1 (Figure 2a and Supplementary Figure S1 ).
Next, we treated shh-EGFP cells with Nutlin-3a, the active enantiomer of Nutlin-3, which disrupts the interaction between p53 and Mdm2, preventing proteasome-mediated p53 degradation. 18 Nutlin-3a and p53 shRNA alter p53 activity in opposite ways. shTrp53 reduces p53 activity by blocking p53 expression, while Nutlin-3a activates p53 by stabilizing the p53 protein. Treatment with Nutlin-3a suppressed activation of the Gli promoter in shh-EGFP cells, as evident by suppression of GFP as well as of expression of the proliferation marker Ki-67 in Shh-stimulated, empty vector-transduced shh-EGFP cells. Nutlin-3a treatment of YFP-WIP1-transduced shh-EGFP cells similarly suppressed activation of the Gli promoter and Ki-67 following Shh stimulation (Figures 2b and c) . And, Nutlin-3a suppressed Shh-stimulated expression of Gli in shh-EGFP cells transduced with empty vector or YFP-WIP1 (Figure 2d ). This suggests that high p53 levels override growth support from Shh or transduced WIP1.
WIP1 enhances Shh signaling in cerebellar GNPs
To understand the significance of high expression or amplification of WIP1 in MB tumorigenesis, we transduced cGNPs from postnatal day seven (P7) wild-type mice with empty vector or YFP-WIP1. This resulted in increased expression of the downstream Shh target genes Gli1 and Ptc1 (Figure 3b ).
To determine dependence on p53 signaling, we transduced wild-type P5 cGNPs with shNC or shTrp53 in combination with empty vector or YFP-WIP1 (Figures 3a and d) . WIP1 overexpression enhanced proliferation, while stimulation with Shh inhibited apoptosis. Furthermore, knockdown of Trp53 did not significantly affect Shh-stimulated proliferation in the presence or absence of overexpressed WIP1 (Figures 3a and c) . This also suggests that WIP1 augments Gli1 through p53-independent pathways. Nutlin3a significantly suppressed Shh-stimulated proliferation of cGNPs transduced with empty vector or YFP-WIP1, which again suggests that high levels of p53 override growth support provided by Shh or transduced WIP1 (Figure 3e ).
WIP1 enhances Shh signaling and proliferation in the neonatal cerebellum To understand the role of WIP1 in MB tumorigenesis, we developed a mouse in which human WIP1 is expressed under the control of the Neurod2 promoter (ND2:WIP1), which has previously been used to drive constitutive expression of activated Smoothened in the developing cerebellum (Figure 4a) . 19 Embryos were screened for ND2:WIP1 transgene expression by conventional PCR (Figure 4b ). WIP1 expression was significantly higher in the P7 cerebellum of ND2:WIP1 transgenic mice compared with age-matched wild-type controls (Figure 4c ). ND2:WIP1 transgenic founder #12 was used in subsequent experiments since WIP1 expression was highest in the cerebellum of these mice by qRT-RT-PCR.
ND2:WIP1 transgenic mice are viable and do not exhibit any morphologic abnormalities, other than fewer cerebellar lobules at P5, versus controls ( Kip1 (p27) mislocalization and increased cGNP proliferation throughout the EGL. 20 Double labeling with Ki-67 and p27 showed that, at P5, the Ki-67+ EGL in ND2:WIP1 and SmoA1/SmoA1 mice is thicker than wild-type mice. Conversely, the p27+ cell layer at the base of the EGL is thicker in wild type compared with ND2:WIP1 and SmoA1/ SmoA1 mice (Figure 4f ). Thus, mis-localization of p27 in the developing cerebellum of ND2:WIP1 transgenic mice may alter cell cycle progression and promote MB formation.
WIP1 promotes MB tumorigenesis in a hedgehog-activated model Previously published reports suggest that increased WIP1 expression alone does not promote formation of de novo tumors. 14, 21 Similarly, we did not detect de novo MBs in ND2:WIP1 mice. However, when we mated ND2:WIP1 mice with SmoA1/SmoA1 mice, the incidence of MBs increased, mice presented with MB symptoms at a younger age and SmoA1/SmoA1; ND2:WIP1+ mice exhibited reduced overall MB-related survival (Figures 5a and b) . (Figure 5d ). In human SHH-activated MBs with focal WIP1 amplification, we validated increased WIP1 expression (Figure 5g ).
Wip1 knockout suppresses MB formation Studies published to date show that Wip1 knockout impairs spermatogenesis. However, Wip1 − / − mice are viable and resistant to tumor formation. 22 No studies to date have described abnormalities in the developing nervous system of Wip1 − / − mice. Using immunohistochemistry, we found that the portion of the EGL in P5 Wip1 − / − mice that stained positive for Ki-67 and the downstream marker of Shh pathway activation, Ccnd1, was thinner than in P5 Wip1+/+ mice ( Figure 6a ). This suggests that the P5 EGL of Wip1 − / − mice contains fewer proliferating Shh-activated cells compared with the EGL of Wip1+/+ mice. Given this finding, and since other groups have shown that Wip1 loss impairs tumor formation, 15, 23 we mated Wip1 − / − mice with
Ptc1 fl/fl) mouse models of Shh-activated MB. In both models, Wip1 knockout significantly suppressed de novo MB formation (Figures 6b and c) . 5 Shh-EGFP cells, media was changed to serum-free media containing vehicle or Shh (3 μg/ml). Cells were transduced with lentivirus containing negative control (shNC) or Trp53 shRNA (shTrp53) in combination with lentivirus containing an empty vector or YFP-tagged WIP1 cDNA (LentiORF-YFP-WIP1), and incubated for another 48 h. Shown is real-time RT-PCR for Gli1 and Trp53, relative to Gapdh and normalized to vehicle-treated, shNC and empty vector-transduced controls, *Po 0.005. (b) Twenty-four hours after plating 1 × 10 5 Shh-EGFP cells, media was changed to serum-free media containing vehicle, 8 μM Nutlin-3a and/or Shh (3 μg/ml). Cells were also transduced with lentivirus containing pLKO.1 empty vector or LentiORF-YFP-WIP1. Forty-eight hours later, cells were fixed in 4% paraformaldehyde, permeabilized, incubated with α-WIP1 or α-Ki-67 antibody, and mounted using media containing DAPI. Scale bar, 100 μm. (c) Quantitation of cells from (b) that express green fluorescent protein (GFP) or Ki-67 per high-power field (HPF). Bars, mean cell counts from 10 representative fields for each condition, *P o0.005. (d) mRNA was used to determine Gli1, relative to Gapdh and normalized to expression in empty vector-transduced vehicle-treated cells, by real-time RT-PCR, *Po0.005. Error bars, standard deviation (s.d.) among replicates of at least three per treatment. All experiments were repeated at least three times. NS, not significant. 6 postnatal day five (P5) cerebellar granule neuron precursor cells (GNPs), media was changed to serum-free media containing vehicle or Shh (3 μg/ml) and cells were transduced with lentivirus containing shNC or shTrp53 in combination with lentivirus containing empty vector or LentiORF-YFP-WIP1. Forty-eight hours later, cells were incubated with 3 μg/ml BrdU for 4 h, fixed in 4% paraformaldehyde (PFA), permeabilized and incubated with α-BrdU antibody, followed by Alexa Fluor 594-conjugated secondary antibody. Representative photomicrographs 48 h after viral transduction are shown. BrdU, red; DAPI, blue. Scale bar, 100 μm. 6 P5 GNPs, media was changed to serum-free media containing vehicle, 8 μM Nutlin-3a and/or Shh (3 μg/ml). Cells were also transduced with lentivirus containing pLKO.1 or LentiORF-YFP-WIP1. Forty-eight hours later, cells were fixed in 4% PFA, permeabilized, incubated with α-Ki-67 antibody and mounted using media containing DAPI (left-hand panel). Scale bar, 100 μm. Quantitation of cells from (c) that express Ki-67, per high-power field (HPF) (right-hand panel), *Po0.005. Bars, mean of cell counts from 10 representative fields for each experimental condition. Error bars, standard deviation (s.d.) among replicates of at least three per treatment. All experiments were repeated at least three times. knocked down Wip1 (not shown) or with CCT007093 inhibited the growth-promoting effects of SAG and potentiated the antiproliferative effects of SANT-1 (Figure 8a, left) . Effects of WIP1 inhibition on cell viability correlated with reduced expression of the downstream Shh target Gli1 in CCT007093-treated SmoA1/ SmoA1; ND2:WIP1+ MB cells (Figure 8a, right) .
We also studied the effects of small molecules that inhibit Shh and WIP1 signaling alone and together in the SmoA1/SmoA1; Wip1+/+ and tamoxifen-induced Math1-cre ER ; Ptc1 fl/fl MB models, which
+; Wip1+/+ mice. Cyclopamine and LDE225, as well as CCT007093, significantly inhibited MB cell proliferation, alone or in combination, under cell culture conditions. However, LDE225, alone or in combination with CCT007093, also significantly increased MB cell death (Figure 8b , right-hand panels).
DISCUSSION
WIP1 is a serine/threonine protein phosphatase that is important in the DNA damage response. Through its phosphatase activity on proteins crucial for cell cycle regulation or DNA damage response, including Atm, p53, Chk1, Chk2, Mdm2, Mdm4, p38MAPK and γ-H2AX, WIP1 functions in a negative feedback control loop to maintain homeostasis following exposure to DNA-damaging agents. 25 However, gene amplification, high-level expression or specific C-terminal mutations can result in WIP1 functioning as an oncoprotein.
On its own, Wip1 overexpression does not promote spontaneous tumor formation. However, Wip1 cooperates with validated oncogenes, including c-myc, Erbb2, Ras and E1A, to transform mouse embryonic fibroblasts.
22,26 Double transgenic mice that express both Erbb2 and Wip1 under control of the MMTV promoter exhibit a shorter onset to the development of breast tumors. 21 And, amplification of the chromosomal locus of WIP1, 17q22-q23, has been described in numerous human malignancies that are wild type for TP53, including MB. 9, 26, 27 By fluorescence in situ hybridization and comparativegenomic hybridization we previously identified 64% of MBs with amplification of the WIP1 locus. 28 We have described increased WIP1 expression in non-Wingless (WNT) activated MBs, 29 a signature that is often associated with inferior patient survival. 30 And, we have shown that increased WIP1 expression in MB is associated with poor overall and event-free survival. Recently, we have shown increased WIP1 expression in Group 3 and 4 MBs, which have a high incidence of metastasis at diagnosis. And, we have described an important interaction between WIP1 and CXCR4 signaling that may promote MB metastasis. 31 Following up on the work of Northcott et al. 9 in which they showed that a subset of MBs that have a gene signature of active SHH signaling also have high-level amplification of the chromosomal locus of WIP1, we found that WIP1 overexpression in NIH/3T3 cells and cGNPs enhanced proliferation and expression of Shh target genes in response to Shh stimulation. Overall, our findings were in agreement with Pandolfi et al. 15 in which they show that WIP1 increased the transcriptional activity of GLI1 in the colon cancer cell line HCT116. Interestingly, neither wild type nor phosphatasedeficient, mutant (WIP1 D314A) WIP1 activated a GLI-dependent promoter in HCT116 cells. But, in patient-derived SSM2c melanoma and MCF7 breast cancer cells, which express high levels of WIP1 at baseline, transfection with exogenous WIP1 increased activation of a GLI-dependent promoter and GLI1 mRNA expression. This suggests that cross-talk between WIP1 and SHH signaling may be modulated by tumor or cell line-specific factors that are still unknown.
Investigators have previously shown that WIP1 inactivates p53 32 and that p53 and GLI1 function in a negative feedback loop. 33 We investigated whether the interaction between WIP1 and SHH signaling in MB is p53 dependent. Using expression plasmids that contain a luciferase reporter, investigators have shown that p53 negatively regulates the activity, localization and expression of GLI1. 34 We found that WIP1 overexpression enhanced proliferation, while stimulation with Shh inhibited apoptosis. Furthermore, knockdown of Trp53 did not significantly affect Shh-stimulated proliferation in the presence or absence of overexpressed WIP1. This suggests that WIP1 augments Gli1 expression through p53-independent pathways. That Nutlin-3a significantly suppressed Shh-stimulated proliferation of cerebellar GNPs transduced with empty vector or YFP-WIP1 suggests that, in cGNPs, the effects of high levels of p53 override whatever growth support is provided by Shh or transduction with WIP1 lentivirus.
To further understand WIP1 mechanisms in vivo, we developed a mouse in which WIP1 is expressed under control of the Neurod2 promoter (ND2:WIP1). Compared with wild-type controls, the EGL of P5 ND2:WIP1 mice exhibited increased proliferation and expression of the Shh downstream target Ccnd1. Although a few 412-month-old ND2:WIP1 mice exhibited lethargy or preferential turning in one direction, we were unable to find histologic evidence of MB in these mice. This is consistent with the findings of other groups that have been unable to promote tumor formation in vivo by overexpressing WIP1 alone, but suggests that activation of growth-promoting signaling pathways by WIP1 may predispose cells in the early pos-natal EGL of ND2:WIP1 mice to malignant transformation in the presence of other oncogenes. 14, 21, 26 Investigators have previously shown that co-injected of RCAS-WIP1 and -Shh expression constructs into neonatal mice increased the incidence of MB.
14 And, knockdown of PTCH1 accelerated the growth of flank xenografts of WIP1 high-expressing patientderived melanoma cells in athymic-nude mice. 15 We validated increased WIP1 expression in SHH-activated MB tissues with focal amplification of the WIP1 locus, compared with cerebellar controls and compared with MBs with balanced alterations in chromosome 17. And, when we mated ND2:WIP1 transgenic with SmoA1/SmoA1 mice, MB incidence increased and survival decreased. This confirmed an important interaction between WIP1 and SHH signaling that promotes MB tumorigenesis.
Since other groups have shown that Wip1 loss inhibits tumor formation 23 and that WIP1 is a viable target for cancer therapy, 15, 25, [35] [36] [37] we examined the effects of Wip1 loss or inhibition in Shh-activated models of MB. Wip1 knockout reduced the thickness of the proliferating Ki-67+ or Ccnd1+ P5 EGL. Wip1 knockout also significantly suppressed MB formation in two independent Shh-activated mouse models of MB. Treatment with a lentivirus that knocks down Wip1 or with the WIP1 inhibitor CCT007093 blocked the effects of Shh stimulation and potentiated the effects of the SHH pathway-inhibiting drugs SANT-1, cyclopamine or the clinically relevant SHH inhibitor, LDE225, on the growth of either SmoA1/SmoA1 or tamoxifen-induced Math1-cre ER +; Ptc1 fl/fl MB cells in vitro. These findings suggest that WIP1 is an important, druggable molecular target for MB treatment.
MATERIALS AND METHODS

Lentiviral particle production and infection
RFP control and YFP-WIP1 Precision LentiORF expression constructs (Thermo Fisher Scientific, Waltham, MA, USA) were modified in the Custom WIP1 modulates SHH in medulloblastoma J Wen et al Cloning Core Facility (CCCF). EGFP-negative control and shTrp53 short hairpin RNA lentiviral expression constructs have been previously described.
31 psPAX2 and pVSVG plasmids (gifts from H Trent Spencer, Emory University, Atlanta, GA, USA). pLKO.1 (gift from Rita Nahta, Emory University). Production and transduction with lentiviral particles were previously described.
29
WIP1 modulates SHH in medulloblastoma J Wen et al
Cell culture
shh-EGFP and shh-LIGHT2 cells (gifts from James Chen, Stanford University, Stanford, CA, USA) have been described previously. 16 Cells were maintained in Dulbecco's modified Eagle's medium medium with high glucose, 1 × PenStrep (100 U/ml penicillin and 100 μg/ml streptomycin), 10% (vol/vol) heat-inactivated fetal bovine serum at 37°C in 5% CO 2 under selection with 400 μg/ml Zeocin (Thermo Fisher Scientific) alone or along with 400 μg/ml G418 Sulfate (Sigma-Aldrich, St Louis, MO, USA). Cells were Kip1 (p27), in the EGL of the cerebellum of P5 wild-type, ND2:WIP1 and SmoA1/SmoA1 mice (n = 3 cerebella per genotype), *P o0.005. Ki-67, red; p27, green; DAPI, blue. Bar, EGL width; ML, molecular layer; IGL, internal granule layer; HPF, high-power field. Error bars, standard deviation (s.d.) among replicates of at least three per group. Scale bars, 100 μm. All experiments were repeated at least three times or in at least three distinct cerebella. 5 MB cells from symptomatic mice were plated in triplicate in serum-containing media and assayed for viability by trypan blue exclusion, *P o0.05. (e) Relative WIP1 expression in human MBs with balanced copy number changes of chromosome 17 (n = 5) or focal amplification of the WIP1 gene locus (n = 4) by Affymetrix SNPs. Both MB groups exhibit a gene signature consistent with activation of hedgehog signaling. Shown for comparison is WIP1 expression in human fetal and adult cerebellum (n = 6, each). Error bars, standard deviation (s.d.) among replicates of at least three per group. All experiments were repeated at least three times.
authenticated by STR profiling within the last 6 months and are screened for mycoplasma contamination every 6 months (MycoAlert Detection Kit; Lonza Group, Allendale, NJ, USA).
Cerebellar GNPs were generated, as described. 38 A Percoll gradient was used to purify re-suspended GNPs, as previously described. 13 Cells were plated onto poly-DL-ornithine-coated 24-well plates with glass coverslips for histology experiments or plated onto poly-DL-ornithine-coated six-well plates for RT-PCR experiments. Shh (3 μg/ml) was added to samples within the Shh treatment groups. Media containing serum was replaced with serum-free media with and without Shh after a 3-h incubation period. 17 were plated per well in 500 μl media containing Dulbecco's modified Eagle's medium with 10% fetal bovine serum and 1% P/S. Twenty-four hours later, cells were changed to Dulbecco's modified Eagle's medium with 0.5% fetal bovine serum and transduced with red fluorescent protein (RFP)-tagged control (RFP-CTRL) or yellow fluorescent protein (YFP)-tagged WIP1 (YFP-WIP1) lentivirus. Twenty-four hours later, cells were stimulated with vehicle or Shh (3 μg/ml) for 24 h. Luciferase activity was assayed using the Dual Luciferase Reporter Assay System (Promega, Fitchburg, WI, USA, #E1910), according to the manufacturer's instructions.
Cell cycle analysis
Forty-eight hours after transducing shh-EGFP cells with control or YFP-tagged WIP1 lentivirus and stimulating with vehicle or 3 μg/ml Shh-N, 10 μM EdU was added to media and incubated for 5 h. Cells were harvested by scraping, fixed, permeabilized and incubated with Click-iT EdU reagents, including FxCycle Violet, as per the manufacturer's protocol (Thermo Fisher Scientific). Samples were analyzed using a BD FACS Canto II cytometer (BD Biosciences, San Jose, CA, USA) with BD FACS Diva software.
Quantitative real-time RT-PCR Total cellular RNA was extracted, as previously described. 29 qRT-RT-PCR reactions containing cDNA, Sybr Green PCR Master Mix (Thermo Fisher Scientific) and primers for WIP1, Gli1, Ptc1, Trp53, and/or Glyceraldehyde-3 Phosphate Dehydrogenase (Gapdh) were run on an ABI 7500 Real-Time PCR 5 shh-EGFP cells, media was changed to serum-free media containing vehicle (Vh), DMSO, CCT007093 (CCT, 5 μM) and/or Shh (3 μg/ml). Cells were also transduced with LentiORF-RFP-CTRL or LentiORF-YFP-WIP1 lentivirus. Forty-eight hours later, cells were fixed in 4% paraformaldehyde, permeabilized, incubated with α-WIP1 or α-Ki-67 antibody, and mounted using media containing DAPI (left-hand panels). Quantification of cells, per highpower field (HPF), that express green fluorescent protein (GFP) or Ki-67 (right-hand panels). Bars, mean of cell counts from 10 representative fields for each experimental condition. (c) Twenty-four hours after plating 1 × 10 6 P5 GNPs, media was changed to serum-free media containing vehicle, 5 μM CCT and/or Shh (3 μg/ml). Cells were also transduced with lentivirus containing pLKO.1 or LentiORF-YFP-WIP1. Fortyeight hours later, cells were fixed in 4% paraformaldehyde, permeabilized, incubated with α-Ki-67 antibody and mounted using media containing DAPI (left-hand panel). Quantification of cells from (c), per high-power field (HPF), that express Ki-67 (right-hand panel). Error bars, standard deviation (s.d.) among replicates of at least three per treatment. Scale bars, 100 μm. All experiments were repeated at least three times. *P o0.005.
Cycler (Thermo Fisher Scientific) using absolute quantification with a standard curve. Primer sequences available upon request. Absolute gene expression was determined based on standard curves. Target gene expression was normalized to Gapdh expression.
Western blotting
Protein was extracted, quantified and probed with antibodies as described. 39 Whole-cell lysates were extracted using RIPA buffer (Cell Signaling Technology Inc., Danvers, MA, USA). Antibodies used ER ; Ptc1 fl/fl mice (left-hand panels), media was changed to serum-free media containing vehicle (Vh), 200 nM SAG, 10 μM cyclopamine (Cyc), 10 μM LDE225 (LDE) or 5 μM CCT, with or without Cyc or LDE. Cells were incubated under tissue culture conditions for another 24 h. Viable cells were determined by trypan blue exclusion (left-hand panel), *P o0.05. Real-time, RT-PCR for Gli1 and Ptc1, relative to Gapdh and normalized to vehicle-treated controls, in cells from (c) (right-hand panels), *P o0.05. Medulloblastoma cells from symptomatic SmoA1/SmoA1; Wip1+/+ were also treated with Vh, 10 μM Cyc, 10 μM LDE or 5 μM CCT, with or without Cyc or LDE, followed by incubation with 3 μg/ml BrdU for 4 h, fixation in 4% paraformaldehyde (PFA), permeabilization and incubation with α-BrdU antibody, followed by incubation with Alexa Fluor 594-conjugated secondary antibody. Shown is quantitation of BrdU (b, top-right panel) or Cleaved Caspase 3 (b, bottom-right panel) immunofluorescence, relative to DAPI using CellProfiler software, *P o0.005. Error bars, standard deviation (s.d.) among replicates of at least three per treatment. All experiments were repeated at least three times.
included p53 (Cell Signaling Technology Inc.), Mdm2 (EMD Millipore, Billerica, MA, USA), WIP1 (Bethyl Laboratories Inc., Montgomery, TX, USA) and β-actin (Sigma-Aldrich). Secondary antibodies Alexa Fluor 680 goat anti-mouse IgG (Thermo Fisher Scientific) or IRDye 800 goat anti-rabbit IgG (Rockland Immunochemicals Inc., Pottstown, PA, USA) were used at a dilution of 1:5000. Immunoblots were imaged as previously described. 29 Tissue handling and IHC Mouse brains were sectioned sagittally down the midline and fixed in formalin. Tissue blocks were paraffin-embedded and cut into 5 μm sections. Following antigen retrieval, tissues were blocked and incubated with α-Ki-67 (1:500; Vector Laboratories Inc., Burlingame, CA, USA, VP-RMO4) or Ccnd1 (1:100; Thermo Fisher Scientific, SP4) overnight at 4°C, and then incubated with biotinylated goat anti-rabbit IgG (1:300; Vector Laboratories Inc., BA-1000). Slides were stained with hematoxylin and mounted using VectaMount (Vector Laboratories Inc.). Images were captured with an Olympus DP70 digital camera, and were analyzed using the DP Controller software package (Olympus America Inc., Center Valley, PA, USA). Images were processed for publication using Adobe Photoshop Elements 5.0 (Adobe Systems Inc., San Jose, CA, USA).
BrdU labeling
BrdU (Thermo Fisher Scientific, #BP 2508250) was added to medium (3 μg/ml) for 4 h, and fixed in 4% paraformaldehyde. Cells were incubated with α-BrdU (BD Biosciences, #347580) (1:1000), and then Alexa Fluor 594-conjuated Affinipure F (ab')2 fragment goat anti-mouse IgG (H+L) secondary antibody (Jackson ImmunoResearch, West Grove, PA, USA, code: 115-586-003). Coverslips were mounted with Vectashield with 4 0 ,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories Inc., H-1500). Images were obtained from 10 representative areas on each coverslip using a Leica DM2500 microscope with a DFC 365FX digital camera and the Leica Application Suite-Advanced Fluorescence software package (Leica Microsystems Inc., Buffalo Grove, IL, USA).
Immunofluorescence quantitation
Quantitation of BrdU or Cleaved Caspase 3-positive cells was performed using CellProfiler. 40 Two analysis pipelines were used to identify nuclear labeling (DAPI or BrdU) or cytoplasm labeling (Cleaved Caspase 3) in TIFF images: (1) color to gray module converted images to grayscale, and (2) identify primary objects module was used to optimize program recognition of individual positive cells. Positive cells were identified based on diameter and fluorescence intensity. BrdU or Cleaved Caspase 3-positive counts were divided by DAPI-positive nuclei counts. Cell counting was single blinded: the experimenter was conscious of experimental details, but the unbiased observer, who counted the cells, was blinded from sample details.
Immunofluorescence
Coverslips were placed into 24-well plates, coated with poly-L-ornithine and seeded with 5 × 10 4 shh-EGFP cells or 1 × 10 6 GNPs and treated as described for proliferation. After 48 h, cells were fixed with 4% paraformaldehyde and blocked, then incubated with α-WIP1 (1:100; Bethyl Laboratories Inc., A300-664A) or Ki-67 (1:500; Vector Laboratories Inc., VPRmo4) overnight at 4°C, then incubated with secondary antibody (1:500; Alexa Fluor 594 goat anti-rabbit IgG, A11012; Thermo Fisher Scientific). Coverslips were mounted on slides with Vectashield with DAP1 (Vector Laboratories Inc., H-1500). High-magnification images were obtained from 10 representative areas on each coverslip using a Leica DM2500 microscope with a DFC 365FX digital camera and Leica Application Suite-Advanced Fluorescence (Leica Microsystems Inc.).
P5 brains were sectioned sagittally down the midline, and fixed in 10% formalin. Following antigen retrieval, tissues were blocked, and incubated with α-Ki-67 (SP6) (1:250 dilution; Abcam, Cambridge, MA, USA, ab16667) overnight at 4°C, followed by incubation with secondary antibody (Alexa Fluor 549 goat anti-rabbit IgG; Thermo Fisher Scientific, A11012). P27 (Kip1) (1:100 dilution; BD Biosciences, 610241) was then added, followed by a second secondary antibody (Alexa Fluor 488 goat anti-mouse IgG; Thermo Fisher Scientific, A11029). Tissues were mounted on slides with Vectashield mounting medium with DAPI (Vector Laboratories Inc., H-1500) and imaged at × 40 as above.
